药物开发 药物开发
Pranav Mishra1,2, Ehsan Esfahani1, Paul Fernyhough1,2
1Division of Neurodegenerative Disorders, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, MB, Canada.
17β雌二醇 (E2) 通过减轻粉样β (Aβ) 诱导的神经炎症和线粒体功能障碍,保护阿尔茨海默病 (AD) 病理. E2治疗恢复了代谢调节者和增强了神经元功能,这表明AD的治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 内分泌学 在内分泌学.
背景情况:
- 阿尔茨海默病 (AD) 涉及神经炎症和线粒体功能障碍,由粉样β (Aβ) 加剧.
- 在衰老和更年期期间失去雌激醇 (E2) 与AD风险增加有关.
- 通过调节线粒体功能和炎症,E2表现出神经保护性.
研究的目的:
- 研究17-β雌二醇 (E2) 对阿尔茨海默病中Aβ诱导的神经炎症和线粒体功能障碍的神经保护作用.
- 探索E2作为对AD的潜在治疗干预措施.
主要方法:
- 主要皮层神经元被培养并用Aβ治疗以诱导AD病理,一些组接受E2预治疗.
- 西部涂抹,MTT,LDH,ELISA和海马XF测试用于评估蛋白质表达,细胞活力,细胞毒性,炎症标志物和线粒体功能.
- 分析了NF-κB激活和pAMPK和PGC-1α等代谢调节者的水平.
主要成果:
- Aβ治疗降低了pAMPK和PGC-1α水平,损害了线粒体功能,并激活了促炎性NF-κB.
- E2预处理恢复了pAMPK和PGC-1α水平,维护了线粒体功能和ATP生产,并减少了NF-κB激活.
- E2减轻了Aβ诱导的神经毒性,并降低了炎症性细胞因子水平.
结论:
- 在初级皮层神经元中,E2显示出对Aβ的显著神经保护作用.
- E2减轻了Aβ诱导的线粒体功能障碍,炎症和神经毒性.
- 通过向线粒体功能障碍和神经炎症,E2具有作为阿尔茨海默病治疗剂的潜力.
更多相关视频
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
相关概念视频
Preclinical Development: Overview
Clinical Trials: Overview
Drug Discovery: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
In Vitro Drug Release Testing: Overview, Development and Validation
Drug Regulation
